Core Insights - C4X Discovery Holdings Ltd has selected a pre-clinical candidate from its oral α4β7 integrin inhibitor programme aimed at treating inflammatory bowel disease (IBD), which supports once-daily dosing and has the potential to be a best-in-class therapy [2][3] Company Overview - C4X Discovery is a pioneering drug discovery company that combines scientific expertise with advanced technologies to develop next-generation oral medicines, focusing on immuno-inflammatory diseases [8] Market Potential - IBD affects over five million people globally and is projected to reach a market size of USD 47.7 billion by 2034, indicating a significant opportunity for C4X Discovery's oral α4β7 integrin inhibitor [3] Treatment Advantages - The oral α4β7 inhibitor offers a convenient treatment option that could advance ahead of biologics, potentially increasing the number of patients treated and improving patient outcomes while reducing the burden on healthcare systems [4] Pipeline and Future Plans - C4X Discovery is advancing multiple programmes, including oral α4β7 and TNFα inhibitors, and a first-in-class PAD4 programme, with plans to continue partnering discussions and generate pivotal data in the coming months [5]